Chemo plus medicine in the spine to prevent lymphoma brain relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your lymphoma is DLBCL that has not been treated yet (confirmed by pathology), and you meet a “high-risk” CNS relapse risk group.
- You have measurable lymphoma spots (on scan) and basic blood counts that are high enough for treatment.
- Your heart function is strong enough (left-heart pump strength at least 50%); you must not have major unstable heart problems or very long QT on ECG.
- Your kidney, liver, and overall health test results are within allowed ranges, and you are well enough to do treatment (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
This trial tests a combination of chemotherapy and a targeted drug (zanubrutinib) for people with a type of lymphoma (DLBCL) that has spread to the brain or spinal fluid. The goal is to see if this treatment can better control the disease and improve outcomes.
This trial tests whether adding either methotrexate or thiotepa to the standard R-CHOP regimen plus orelabrutinib can better treat diffuse large B-cell lymphoma (DLBCL) that has spread to the central nervous system (brain or spinal cord). The goal is to see if these combinations improve outcomes for patients with this type of lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.